secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001104659-25-076837
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Q2 net income $54.8M driven by $225M TRELEGY royalty sale; YUPELRI sales +22%
--------------------------------------------------------------------------------

- YUPELRI net sales $66.3M (Viatris-recorded) up 22% YoY; Q2 implied 35% share $23.2M.
- Completed sale of TRELEGY royalty interest to GSK for $225M; net gain of $75.1M.
- Pivotal Phase 3 CYPRESS study enrollment nearing completion; top-line data ~6 months later.
- Cash $339M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.
- Non-GAAP net loss from operations improved to $4.2M from $6.3M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925076837/0001104659-25-076837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925076837/tm2523183d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-076837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer